Publications
46
Citations
709
Est. group size
~1
Recurring co-author estimate
Active years
27
Publishing since 1999
Janet L. Oblinger's research focuses on developing and testing potential drug treatments for tumors linked to the genetic condition neurofibromatosis type 2 (NF2), including meningiomas (tumors of the membranes covering the brain and spinal cord) and schwannomas (tumors of nerve-supporting cells). Her recent work evaluates drugs that block specific cell-growth pathways (such as mTOR, proteasome, and histone deacetylase inhibitors) and combination therapies, often using laboratory and animal models, with the goal of slowing tumor growth or preventing hearing loss caused by these tumors.
Publication output was low and sporadic from 2017-2021, spiked sharply in 2023, and has since tapered off through 2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Combining Brigatinib with mTOR Inhibition to Effectively Treat NF2-SWN–Associated and Sporadic <i>NF2</i> -Deficient Meningiomas
Cancer Research Communications · 2025
- Preclinical evaluation of the third-generation, bi-steric mechanistic target of rapamycin complex 1-selective inhibitor RMC-6272 in <i>NF2</i>-deficient models
Neuro-Oncology Advances · 2024
- Enhanced Tumor Control and Hearing Loss Prevention Achieved with Combined Immune Checkpoint Inhibitor and Anti-VEGF Therapy in Vestibular Schwannoma Model
bioRxiv (Cold Spring Harbor Laboratory) · 2024
- Proteasomal pathway inhibition as a potential therapy for NF2-associated meningioma and schwannoma
Neuro-Oncology · 2023
- Supplementary Figures 1-10, Table 1 from Histone Deacetylase Inhibitor AR-42 Differentially Affects Cell-cycle Transit in Meningeal and Meningioma Cells, Potently Inhibiting <i>NF2</i>-Deficient Meningioma Growth
2023
- Supplementary Methods, Figures Legends 1-10 from Histone Deacetylase Inhibitor AR-42 Differentially Affects Cell-cycle Transit in Meningeal and Meningioma Cells, Potently Inhibiting <i>NF2</i>-Deficient Meningioma Growth
2023
- Supplementary Methods, Figures Legends 1-10 from Histone Deacetylase Inhibitor AR-42 Differentially Affects Cell-cycle Transit in Meningeal and Meningioma Cells, Potently Inhibiting <i>NF2</i>-Deficient Meningioma Growth
2023
- Supplementary Figures 1-10, Table 1 from Histone Deacetylase Inhibitor AR-42 Differentially Affects Cell-cycle Transit in Meningeal and Meningioma Cells, Potently Inhibiting <i>NF2</i>-Deficient Meningioma Growth
2023
- Data from Histone Deacetylase Inhibitor AR-42 Differentially Affects Cell-cycle Transit in Meningeal and Meningioma Cells, Potently Inhibiting <i>NF2</i>-Deficient Meningioma Growth
2023
- Data from Histone Deacetylase Inhibitor AR-42 Differentially Affects Cell-cycle Transit in Meningeal and Meningioma Cells, Potently Inhibiting <i>NF2</i>-Deficient Meningioma Growth
2023
- Neuro-Oncology×4
- PLoS ONE×1
- Laryngoscope Investigative Otolaryngology×1
- Experimental Neurology×1
- Molecular Cancer Therapeutics×1
- Long‐Sheng Chang
Medicine · The Ohio State University
- Eric Hawley
Medicine · Indiana University
- Chi Zhang
Medicine · Indiana University
- D. Wade Clapp
Medicine · Indiana University
- Abbi E. Smith
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile